Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

The company's subsidiary, Biocon Pharma, has received final approvals for its two ANDAs - Lenalidomide capsules and Dasatinib ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...

The company announced that it has secured three orders valued at around ₹500 crore from Power Grid Corporation of India Ltd ...

Pharma major, Biocon Pharma, has received final approvals from the U.S. Food and Drug Administration (FDA) for its ...

Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide ...

Biocon Ltd is quoting at Rs 320.8, up 1.91% on the day as on 12:49 IST on the NSE. The stock is up 16.87% in last one year as compared to a 0.46% slide in NIFTY and a 4.57% slide in the Nifty Pharma ...

Track key stocks like Biocon, Jio Financial, and Adani Wilmar making headlines today. Discover market impacts and stay ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

The company also received tentative FDA approval for its ANDA for Rivaroxaban, an anticoagulant used to treat deep vein ...